Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Beuselinck

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
European Urology Oncology|May 17, 2020
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell CarcinomaEduard Roussel, Riccardo Campi, Alessandro Larcher, et al.
JAMA Oncology|October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
The Lancet. Oncology|March 5, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort studyNieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, et al.
Human Molecular Genetics|February 6, 2015
Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2Nick Orr, Frank Dudbridge, Nicola Dryden, et al.
Journal of Medical Genetics|September 7, 2016
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSMelissa C Southey, David E Goldgar, Robert Winqvist, et al.
Gynecologic Oncology|May 6, 2015
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, Antoinette Hollestelle, Frederieke H van der Baan, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
European Urology Oncology|May 17, 2020
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell CarcinomaEduard Roussel, Riccardo Campi, Alessandro Larcher, et al.
JAMA Oncology|October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
The Lancet. Oncology|March 5, 2019
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort studyNieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, et al.
Human Molecular Genetics|February 6, 2015
Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2Nick Orr, Frank Dudbridge, Nicola Dryden, et al.
Journal of Medical Genetics|September 7, 2016
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSMelissa C Southey, David E Goldgar, Robert Winqvist, et al.
Gynecologic Oncology|May 6, 2015
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, Antoinette Hollestelle, Frederieke H van der Baan, et al.
Pageof 12